FDA Advice On Drug Risks Not Always Followed By Health Care Providers
Executive Summary
A study finds that health care providers are most likely to heed FDA advisories if they are about a specific drug, rather than a class of drugs, and alternative treatments are available.
You may also be interested in...
US FDA’s ‘Bad Ad’ Program Snares Paragard Contraceptive TV Video Promo
CooperSurgical is hit with second letter for misleading promotion of its copper-containing intrauterine contraceptive. Video lacked any safety information, agency says in request for corrective communication.
COVID-19 Vaccine Manufacturers Are Not Enthusiastic About Using Defense Production Act
Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.
Clinical Trial Diversity: We Must ‘Turn This Moment Into A Movement’
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: